Results 261 to 270 of about 2,936,789 (384)

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source

A novel biochip-based liquid biopsy for extracellular vesicle RNA detection in prostate cancer. [PDF]

Cancer Biol Ther
Diao Y, Nan A, Li R, Ding T, Li Z, Wang J, Zhu B, Li J, Yang L, Zhou L, Liu J, Hao X.   +11 more
europepmc   +1 more source

Protein Z: A putative novel biomarker for early detection of ovarian cancer [PDF]

, 2016
Matthew R. Russell, Michael J. Walker, Andrew J.K. Williamson, Aleksandra Gentry‐Maharaj, Andy Ryan, Jatinderpal Kalsi, Steven J. Skates, Alfonsina D’Amato, Caroline Dive, Maria Pernemalm, P. C. Humphryes, Evangelia‐Ourania Fourkala, Anthony D. Whetton, Usha Menon, Ian Jacobs, R. L. Graham   +15 more
openalex   +1 more source

Metabolomics: beyond biomarkers and towards mechanisms

Nature reviews. Molecular cell biology, 2016
C. Johnson, J. Ivanisevic, G. Siuzdak
semanticscholar   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain-Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease. [PDF]

J Neurochem
Dulewicz M, Kac PR, Ortiz FG, Karikari TK, Kulczyńska-Przybik A, Mroczko B, Turton M, Harrison P, Maler M, Oberstein T, Kornhuber J, Hanrieder J, Zetterberg H, Blennow K, Lewczuk P.   +14 more
europepmc   +1 more source

Urinary Phthalate Biomarker Concentrations and Postmenopausal Breast Cancer Risk [PDF]

, 2019
Katherine W. Reeves, Mary Díaz Santana, JoAnn E. Manson, Susan E. Hankinson, R. Thomas Zoeller, Carol Bigelow, Susan R. Sturgeon, Donna Spiegelman, Lesley F. Tinker, Juhua Luo, Bertha Chen, Jaymie R. Meliker, Matthew R. Bonner, Michele L. Coté, Ting‐Yuan David Cheng, Antonia M. Calafat   +15 more
openalex   +1 more source

Multi‐Omics Integration for Advancing Glioma Precision Medicine

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Gliomas are among the most malignant and aggressive tumors of the central nervous system, characterized by the absence of early diagnostic markers, poor prognosis, and a lack of effective treatments. Advances in high‐throughput technologies have facilitated a refined molecular classification of gliomas, incorporating genetic features. However,
Maria Guarnaccia, Valentina La Cognata, Giulia Gentile, Giovanna Morello, Sebastiano Cavallaro   +4 more
wiley   +1 more source

Determinants of Intergrader Agreement for Key Retinal Photography and OCT Biomarkers in AMD. [PDF]

Transl Vis Sci Technol
Trinh M, Duong A, Cheung R, Chen S, Ng D, Friedrich J, Hodge C, Nivison-Smith L, Ly A.   +8 more
europepmc   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source